Zynex Medical COO Discusses Expanding Role in Non-opioid Pain Management | NASDAQ:ZYXI
A Note On Zynex, Inc.'s (NASDAQ:ZYXI) ROE and Debt To Equity
Zynex's (NASDAQ:ZYXI) Soft Earnings Are Actually Better Than They Appear
Results: Zynex, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Earnings Call: Zynex Reports Steady Q3 Growth, Plans for Future Expansion
Q3 2024 Zynex Inc Earnings Call
RBC Capital Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $11
Zynex Analyst Ratings
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Raises Target Price to $17
Zynex's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
Express News | Zynex, Inc. : H.c. Wainwright Raises Target Price to $17 From $16
Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript Summary
Zynex | 10-Q: Q3 2024 Earnings Report
Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates
Zynex Sees Pain Management Orders Increase in Q3 Following FDA Approval | NASDAQ:ZYXI
Zynex | 8-K: Zynex Reports Third Quarter 2024 Financial Results
Express News | Zynex Shares up 5.4% After the Bell Following Results
Express News | Zynex Q3 2024 GAAP EPS $0.07 Beats $0.06 Estimate, Sales $49.966M Miss $50.827M Estimate
Express News | Zynex Inc Outlook Q4 2024 Rev Is Estimated to Be at Least $53.6 Mln
Express News | Zynex Outlook FY EPS USD 0.2